Skip to main content
Effective Health Care Program

  • Jan. 1, 2005
    Topic Initiated
  • Jan. 9, 2006
    Draft Key Questions
  • Nov. 1, 2007
    Systematic Review

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension

Systematic ReviewArchived

People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.

Archived: This report has been updated.

Excerpt

In this comparative effectiveness review, we examine the scientific literature on angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs, or angiotensin receptor blockers) for individuals with hypertension regarding their relative benefits (blood pressure control, cardiovascular risk reduction, cardiovascular events, quality of life, and other outcomes), as well as relative risks (safety, adverse events, tolerability, persistence, and adherence). In addition, we will examine the clinical determinants of these outcomes with a focus on the long-term impact.